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Capecitabine is an orally active prodrug of ﬂuorouracil and is extensively used as an antineoplastic agent. It is converted to 5-
Fluorouracil in the liver and tumor tissues. Warfarin is an anticoagulant agent for preventing and treating venous and arterial
thrombosisandembolismandismetabolizedbycytochromeP450isoenzymesintheliver.Preclinicalinvitrostudiesusinghuman
liver microsomes report no inhibitory eﬀects between capecitabine and substrates of cytochrome P. However, the concomitant
administration of capecitabine and warfarin resulted in INR elevation in the cases previously reported in the literature. The exact
mechanism of this interaction is unknown but may be related to downregulation of cytochrome P450 2C9 by capecitabine or its
metabolites. We report on the possible adverse interaction between capecitabine and warfarin in a patient with metastatic breast
cancer and critically review the existing literature on this topic. Physicians should be aware of adverse reactions arising from the
combined use of capecitabine and warfarin. In the light of the current data, INR levels should be closely monitored in patients
using these drugs together.
1.Introduction
Capecitabine is an orally administered prodrug of 5-
ﬂuorouracil (5-FU) that mimics continuous infusion of 5-
FU and generates 5-FU preferentially at the tumor site. In
vitro human liver microsome assays have not suggested any
signiﬁcant potential for interaction between capecitabine
or its metabolites and drugs which are substrates for the
cytochrome P450 (CYP) isoenzymes 1A2, 2A6, 2C9, 2C19,
2D6, 2E1, or 3A4 (http://www.rocheusa.com/products/
xeloda/pi.pdf),whichwouldincludeanticoagulantcoumarin
derivates. By contrast, several case reports in the lit-
erature have provided clinical evidence for a possible
interaction between capecitabine and coumarin derivatives
[1–5]Ar e t r o s p e c t i v es t u d y[ 6] investigated coagulation
abnormalitiesinpatientsreceivingconcomitantcapecitabine
and warfarin, ﬁnding an INR >3 in one third of the
patients on warfarin versus 4% for those not on war-
farin, with a higher incidence of bleeding in the ﬁrst
group.
2.CaseReport
A 59-year-old female with metastatic breast cancer (sites
of metastases were bone and lung without liver involve-
ment) was receiving chronic minidose of warfarin ther-
apy (1mg/day) for prophylaxis against catheter-associated
thrombosis. Her prior chemotherapy included an adria-
mycin-based regimen given until disease progression. She
had an hormone-receptor negative and high grade tumour,
but she was in good general conditions, with an ECOG
performance status of 0 and a life expectancy of more than
3 months. The laboratory tests were within the normal limits
and her cardiac function was normal. The international
normalized ratio (INR) level was monitored every week
and was, prior to initiating capecitabine, always under the
value of 2. In may 2005 she received the ﬁrst course of
chemotherapy using capecitabine 1000mg/m2orally twice
daily for a period of 14 days, followed by a rest period of 7
days and intravenous (iv) docetaxel 75mg/m2 on day 1 and
then every 3 weeks. Dexamethasone 20mg was administered2 Case Reports in Medicine
orally the night before and the day of chemotherapy and
then at dose of 8mg twice daily for a period of 2 days after
docetaxel administration. Ondansetron, 8mg twice daily,
was given as an antiemetic on the day of docetaxel treatment.
Prior to the docetaxel administration, ranitidine 50mg was
infused iv over 15min, followed by 10mg chlorpheniramine.
Twenty-one days after initiating capecitabine, the patient’s
INR was markedly elevated (8, 87). Neither symptoms nor
signs of bleeding were detected. The patient did not report
any changes in dietary habits or physical activities, use
of other drugs, alcohol or smoke, presence of fever or
hyperthyroidism that could explain her condition. Twenty-
four hours after the iv administration of Vitamin K 10mg
the INR value had dropped to 1.19. The warfarin was
withheld and the patient did not develop any complications.
The patient was treated with low molecular weight heparin
subcutaneusly and the chemotherapy regimen was restarted
without alterations of the coagulation parameters.
3. Review of the Literatureand Discussion
Warfarin exerts its anticoagulant eﬀect by interfering with
the hepatic synthesis of vitamin K-dependent clotting factors
II, VII, IX, and X and proteins C and S. The pharma-
cokinetic (PK) and pharmacodynamic (PD) properties of
warfarin, as well as its narrow therapeutic index make it
particularly susceptible to interactions with other drugs, and
increasedprothrombintimemonitoringandwarfarindosing
adjustments are required to maintain safe and eﬀective
anticoagulation. Minidose (1mg/d) warfarin is often utilized
in clinical practice to prevent venous thrombosis in cancer
patients [7]a sw e l la sf o rt h r o m b o t i cp r o p h y l a x i sf o rc e n t r a l
venous catheters [8]. Minidose warfarin is considered safe
and monitoring of the prothrombin time is not needed.
Capecitabine is indicated, alone or in combination with
other drugs, for the treatment of patients with metastatic
breast cancer. Capecitabine is also approved for use in
metastatic colorectal cancer. Capecitabine is a ﬂuoropyrim-
idine carbamate which is enzymatically converted to 5-FU
in vivo [9] preferentially at the tumour site. Capecitabine is
readily absorbed by the gastrointestinal tract. In the liver, a
60kDa carboxylesterase hydrolyzes much of the compound
to 5 -deoxy-5-ﬂuorocytidine (5 -DFCR). Cytidinedeami-
nase, an enzyme found in most tissues, including tumors,
subsequently converts 5 -DFCR to 5 -deoxy-5-ﬂuorouridine
(5 -DFUR). The enzyme, thymidine phosphorylase (dThd-
Pase), then hydrolyzes 5 -DFUR to the active drug, 5-FU.
Many tissues throughout the body express thymidine phos-
phorylase. Some human carcinomas express this enzyme
in higher concentrations than surrounding normal tissues.
A recent study suggests that patients with high levels of
intratumoral Thymidine phosphorylase expression are the
ideal candidates for capecitabine-based chemotherapy [10].
Plasma protein binding of capecitabine and its metabolites
is less than 60% and is not concentration dependent.
Capecitabine and its metabolites are predominantly excreted
in urine, fecal excretion is minimal. The major metabolite
excreted in urine is the  αﬂuoro-β-alanine [FBAL] which
represents 57% of the administered dose. About 3% of
the administered dose is excreted in urine as unmodiﬁed
drug. Drugs may interact with warfarin through PD or
PK mechanisms. PD mechanisms for drug interactions
with warfarin are synergism (impaired hemostasis, reduced
clotting factor synthesis), competitive antagonism (vitamin
K), and altered physiologic control loop for vitamin K
metabolism(hereditaryresistance).PKmechanismsfordrug
interactions with warfarin are mainly enzyme induction,
enzyme inhibition, and reduced plasma protein binding. It
is important to mention that some drugs may interact by
more than one mechanism. The mechanism of action for
the interaction between warfarin and capecitabine is not
clear, but may be related to downregulation of CYP2C9 by
capecitabine or its metabolites. Moreover, capecitabine has a
low potential for PK interactions related to plasma protein
binding. An important study was conducted in two clinical
centers in Scotland and United Kingdom with the primary
objective to investigate in detail the eﬀect of capecitabine on
the pharmacokinetics and pharmacodynamics of warfarin in
a clinical setting [11]. In this study, 3 women and 3 men
suﬀering from metastatic breast or colorectal cancer were
enrolled. This study assessed the inﬂuence of capecitabine
on the PK (Plasma concentrations) and PD (INR and Factor
VII) of warfarin. Plasma concentrations of capecitabine and
its metabolites were not inﬂuenced by warfarin. None of the
patients had concomitant treatments which were CYP2C9
inducers or inhibitors. This study clearly showed a marked
INR elevation in the presence of combined capecitabine and
warfarin treatment. Mean baseline factor VII levels dropped
whileoncapecitabinetherapy,potentiallycontributingtothe
observed PD interaction, though this eﬀect did not reach
statistical signiﬁcance.
Warfarin consists of a pair of enantiomers that are
extensively and diﬀerently metabolized by human CYP
isoenzymes [12]. Descriptive and comparative statistics of
the PK of the two enantiomers of warfarin (S- and R-
Warfarin) on days 1 and 61 revealed that higher exposure
to S-warfarinwasobtainedwithconcomitantadministration
of warfarin plus capecitabine compared with warfarin alone.
Coadministration of capecitabine increased the area under
the plasma concentration time curve from 0 to inﬁnity
(AUC0−∞)o fS-warfarin by 57% and its elimination half-life
(t1/2) by 51%. Apparent clearance (CL/F) was decreased by
36%. Time to reach maximum plasma concentration (tmax)
wasdoubled,butthemaximumplasmaconcentration(Cmax)
of S-warfarin was unaﬀected. In contrast, comparison of
the PK parameters of R-warfarin on days 1 and 61 revealed
only minor diﬀerences. R-warfarin is primarily metabolized
by CYP1A2 and CYP3A4, while S-warfarin, the more active
enantiomer, is metabolized almost exclusively by CYP2C9
[13, 14]. These data suggest that in humans capecitabine or
its metabolites may be interacting with CYP2C9, but that
they are less likely to be having any major eﬀect on CYP3A4
or CYP1A2. Clinically relevant thromboses are relatively
common within the oncology setting, in association with
either the underlying malignancy or its treatment [15]. In
a more recent study, patients with malignancy, compared
with nonmalignant patients, had a statistically signiﬁcant
increase in overall incidence of recurrent thromboembolicCase Reports in Medicine 3
events (27.1 v 9.0, respectively, per 100 patient-years) as well
as bleeding (13.3 v 2.1, respe., per 100 patient-years) [16].
In both groups of patients, the incidence of thromboembolic
events was lower when the INR was above 2.0 compared
with below 2.0. Therapeutic or prophylactic anticoagulation
with coumarin derivatives is therefore a frequent backdrop
to anticancer intervention with chemotherapeutic agents
[17]. The capecitabine-warfarin interaction is clinically
signiﬁcant, requiring a black box warning in the package
insert. The underlying mechanism of this interaction seems
to be the enzyme downregulation, rather than direct enzyme
inhibition [1]. In addition, several case series document-
ing interactions between warfarin and 5-FU, suggest the
potential for a more general ﬂuoropyrimidine-warfarin class
eﬀect [18–20]. The INR elevation may occur when 5-FU
is given along with either low and full-doses of warfarin
[18, 19, 21, 22]. In a study [21] the incidence of INR
elevation was observed in 38 of 94 patients (40%) treated
with Folfox regimen (5-FU, Oxaliplatin, leucovorin) and
concomitantminidoseofwarfarin.Interestingly,inthisstudy
all patients with INR abnormalities had normal platelet
counts and none had grade II–IV hepatic toxicity and INR
elevations were observed more often in patients treated with
the full dose of Folfox. Since the ﬁnal step of the activation
cascade of capecitabine generates 5-FU, it is reasonable to
speculate that the noted clinical interaction between 5-FU or
capecitabine and warfarin may be occurring through similar
mechanisms. There is no direct evidence to conﬁrm this, but
it is worthy of remark that in clinical cases a long time delay
has been reported before evidence of interaction between
capecitabine and warfarin. Similar delays in the onset of
clinically relevant interactions have been noted for 5-FU,
and 5-FU administration does modulate the constitutive
expression of certain CYP isoenzymes in a whole rat model
[23].Treatmentwith5-FUproducedasigniﬁcantdecreasein
the total serum clearance value of S-enantiomer of warfarin
in rats [24]. A direct PD interaction between capecitabine
or 5-FU and warfarin, involving vitamin K and/or levels of
active clotting factors could maybe have contributed to the
observedINRchanges.5-FU,andbyextension,capecitabine-
induced mucositis within the gastrointestinal tract may limit
the intake and/or the absorption of vitamin K, increasing the
sensitivity of patients to vitamin K antagonists, such as war-
farin. Nevertheless, an eﬀect on vitamin K intake/absorption
is unlikely to be a major contributing factor, considering
that in the literature no clear links between the severity of
ﬂuoropyrimidinetoxicityinthegastrointestinaltractandthe
degree of INR elevation in the presence of warfarin have
been noted. A retrospective study of 77 patients [25]w h o
received capecitabine was performed to analyze coagulation
abnormalities with or without warfarin. Thirteen patients
(11 on warfarin) had an INR >3 (range, 3.23–11.5), resulting
in a probability of an INR >3 of 32% in the warfarin
group versus 4% for those not on warfarin. The incidence
of bleeding at 130 days of treatment with capecitabine was
18% with warfarin versus 2% without. Bleeding episodes
were not signiﬁcantly diﬀerent between patients with or
without liver involvement (4 of 40 episodes versus 3 of
37 episodes, resp.; P = .12). Patients with an INR >3
were evenly distributed between those with or without
liver involvement (6 of 40 patients versus 7 of 37 patients,
resp.). No INR increases persisted after discontinuation of
capecitabine. Recently, the ﬁrst case of markedly increased
anticoagulant activity of warfarin when used in combination
with doxiﬂuridine has been reported [26], clearly indicating
that the anticoagulant activity of warfarin was markedly
increased by the concomitant use of doxiﬂuridine as well as
capecitabine or 5-Fu. Larger studies with capecitabine and
otherﬂuoropyrimidineswillberequiredinthefuturetofully
investigate the exact mechanism by which the interaction
occursandtounderstandtheextenttowhichdirecteﬀectson
clotting factor activity levels contribute toward INR changes
in any noted ﬂuoropyrimidine-warfarin interaction.
4. Conclusions
Several case reports in the literature have provided clinical
evidence that ﬂuorouracil-based chemotherapy regimens
may potentiate the eﬀects of coumarin derivatives. Pos-
sible interactions between warfarin and capecitabine have
been reported and may occur at any time. In addition, a
study [11] demonstrates a clear PD interaction between
capecitabine and S-warfarin, resulting in exaggerated anti-
coagulant activity. This interaction is probably due to an
inhibition of cytochrome P450 2C9 by capecitabine and/or
its metabolites. These events occurred in patients with and
without liver metastases. It is reasonable to speculate that
the interactions between ﬂuoruracil or capecitabine and
warfarin may be occurring through similar mechanisms.
These events occur within several days and up to several
months after initiating ﬂuoropyrimidine therapy. These data
provide an obvious justiﬁcation for the advice that patients
receiving concomitant oral warfarin anticoagulant therapy
and a ﬂuoropyrimidine should have their INR monitored
closely throughout treatment and for 1 month after and
their warfarin dose adjusted accordingly. This is partic-
ularly relevant to patients receiving long-term treatment
whose warfarin dose may have been considered to be
stable before starting a ﬂuoropyrimidine. In the event of
severe or uncontrollable interactions, if anticoagulation is
still indicated, noncoumarin-based approaches, for example,
with low molecular weight heparin, should be considered as
an alternative.
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